Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.
Published in Journal of clinical oncology : official journal of the American Society of Clinical Oncology • May 1, 2007
Authors:,,
Eric Van Cutsem
Marc Peeters
Salvatore Siena
Abstract
PURPOSE: Panitumumab is a fully human monoclonal antibody directed against the epidermal growth factor receptor (EGFR). We compared the activity of panitumumab plus best supportive care (BSC) to that of BSC alone in patients with metastatic colorectal cancer who had progressed after standard chemoth...
Finding related papers...
Discussions
(0)No comments yet
Be the first to share your thoughts!